Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine whether treatment of patients with depression according to the Collabri Model is more effective in reducing symptoms compared to treatment as usual (TAU)
Background:
Depression is a common disease mostly treated in general practice. Diagnose and evidence based treatment in general practice today is not optimal (e.g. lack of continuity in disease management and lack of treatment opportunities).
International studies show effect of collaborative care on depression, but is not directly applicable into a Danish context.
A Danish model for collaborative care treatment of people with depression, generalized anxiety disorder, social phobia and panic disorder (the Collabri Model) is developed. The Collabri model consists of a multi-professional approach to treatment, scheduled monitoring and review, enhanced inter-professional communication and a structured treatment plan.
Objectives:
to investigate the effect of the Collabri model for depression and further investigate two methods for detection of depression; standard detection and case finding.
Methods:
Two researcher-blinded cluster-randomized controlled studies with an intervention group (treatment according to the Collabri model) and a control group (TAU). Participants are 480 patients with depression consulting their general practitioner.
Results:
Primary outcome for the collaborative care study on depression is depression symptoms, measured with BDI at 6 months.
Discussion:
The results will contribute new knowledge on collaborative care for depression and anxiety in Danish conditions.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Treatment according to the Collabri model | Experimental | Participants in this group will recive treatment according to the Collabri model which is a Danish model for collaborative care between primary and secondary care for depression, social phobia, generalized anxiety and panic disorder |
|
| Treatment as usual | No Intervention | Control group. Participants in this group will recive treatment as usual. This means that participants will recive treatment corresponding to what their GP normally would offer as treatment. E.g. this could be refferal to a psychologist or psychiatrist and/or medicine. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Treatment according to the Collabri model | Other | The Collabri Model is a complex intervention and consists of a number of treatment modalities. The Collabri Model includes the following elements: A multi-professional approach to treatment including a care manager, scheduled monitoring and review, enhanced inter-professional communication and a structured treatment plan. It further integrates: Recruitment of staff with psychiatric experience, training of general practitioner and care manager, use of instruments for detection and follow-up, education and treatment of the patient, supervision from a psychiatric specialist, guided self-help, patient- and relative involvement and a stepped care approach to treatment where treatment is always commenced on the least invasive and least resource-demanding level. |
| Measure | Description | Time Frame |
|---|---|---|
| Degree of depression measured by the Beck Depression Inventory (BDI) | The measure is self-reported | At 6 months follow up after baseline |
| Measure | Description | Time Frame |
|---|---|---|
| Degree of anxiety measured by the Beck Anxiety Inventory (BAI) | The measure is self-reported | At 6 months follow up after baseline |
| Psychological stress measured with the Symptom Checklist (SCL-92) |
| Measure | Description | Time Frame |
|---|---|---|
| Degree of depression measured by the Beck Depression Inventory (BDI) | The measure is self-reported | At 15 months follow up after baseline |
| Degree of anxiety measured by the Beck Anxiety Inventory (BAI) |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Lene F Eplov, MD PhD | Mental Health Center Copenhagen | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Mental Health Centre Copenhagen | Copenhagen | Denmark |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 33962564 | Derived | Brinck-Claussen UO, Curth NK, Christensen KS, Davidsen AS, Mikkelsen JH, Lau ME, Lundsteen M, Csillag C, Hjorthoj C, Nordentoft M, Eplov LF. Improving the precision of depression diagnosis in general practice: a cluster-randomized trial. BMC Fam Pract. 2021 May 7;22(1):88. doi: 10.1186/s12875-021-01432-w. | |
| 33203365 | Derived |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003863 | Depression |
| ID | Term |
|---|---|
| D001526 | Behavioral Symptoms |
| D001519 | Behavior |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
The measure is self-reported
| At 6 months follow up after baseline |
| Functional impairment measured with the Global Assessment of Functioning (GAF-F split version) | The measure is obtained through a semi-structured interview | At 6 months follow up after baseline |
The measure is self-reported
| At 15 months follow up after baseline |
| Psychological stress measured with the Symptom Checklist (SCL-92) | The measure is self-reported | At 15 months follow up after baseline |
| Functional impairment measured with the Global Assessment of Functioning (GAF-F split version) | The measure is obtained through a semi-structured interview | At 15 months follow up after baseline |
| Quality of life measured with the WHO-5 | The measure is self-reported | At 6 months follow up after baseline |
| Quality of life measured with the WHO-5 scale | The measure is self-reported | At 15 months follow up after baseline |
| Personal and social performance measured with the Personal and Social Performance scale (PSP) | The measure is obtained through a semi-structured interview | At 6 months follow up after baseline |
| Personal and social performance measured with the Personal and Social Performance scale (PSP) | The measure is obtained through a semi-structured interview | At 15 months follow up after baseline |
| Side effects measured by the PRISE questionnaire | The measure is self-reported | At 6 months follow up after baseline |
| Side effects measured by the PRISE questionnaire | The measure is self-reported | At 15 months follow up after baseline |
| Health-related quality of life measured with the EQ-5D | The measure is self-reported | At 6 months follow up after baseline |
| Health-related quality of life measured with the EQ-5D | The measure is self-reported | At 15 months follow up after baseline |
| Functional impairment measured with Sheehan Disability Scale (SDS) | The measure is self-reported | At 6 months follow up after baseline |
| Functional impairment measured with Sheehan Disability Scale (SDS) | The measure is self-reported | At 15 months follow up after baseline |
| Sick leave | The measure is obtained from the Danish DREAM database | At 6 months follow up after baseline |
| Sick leave | The measure is obtained from the Danish DREAM database | At 15 months follow up after baseline |
| Self-efficacy measured with the subscale "Obtain Help from Community, Family, Friends" from the Chronic Disease Self-Efficacy Scale | The measure is self-reported | At 6 months follow up after baseline |
| Self-efficacy measured with the subscale "Obtain Help from Community, Family, Friends" from the Chronic Disease Self-Efficacy Scale | The measure is self-reported | At 15 months follow up after baseline |
| Self-efficacy measured with the subscale "Control/Manage Depression Scale" from the Chronic Disease Self-Efficacy Scale | The measure is self-reported | At 6 months follow up after baseline |
| Self-efficacy measured with the subscale "Control/Manage Depression Scale" from the Chronic Disease Self-Efficacy Scale | The measure is self-reported | At 15 months follow up after baseline |
| Self-efficacy measured with the subscale "Personal Control" from The Revised Illness Perception Questionnaire (IPQ-R) | The measure is self-reported | At 6 months follow up after baseline |
| Self-efficacy measured with the subscale "Personal Control" from The Revised Illness Perception Questionnaire (IPQ-R) | The measure is self-reported | At 15 months follow up after baseline |
| Apathia | The measure is obtained through a semi-structured interview | At 6 months follow up after baseline |
| Apathia | The measure is obtained through a semi-structured interview | At 15 months follow up after baseline |
| Curth NK, Brinck-Claussen UO, Hjorthoj C, Davidsen AS, Mikkelsen JH, Lau ME, Lundsteen M, Csillag C, Christensen KS, Jakobsen M, Bojesen AB, Nordentoft M, Eplov LF. Collaborative care for depression and anxiety disorders: results and lessons learned from the Danish cluster-randomized Collabri trials. BMC Fam Pract. 2020 Nov 18;21(1):234. doi: 10.1186/s12875-020-01299-3. |
| 28732523 | Derived | Brinck-Claussen UO, Curth NK, Davidsen AS, Mikkelsen JH, Lau ME, Lundsteen M, Csillag C, Christensen KS, Hjorthoj C, Nordentoft M, Eplov LF. Collaborative care for depression in general practice: study protocol for a randomised controlled trial. Trials. 2017 Jul 21;18(1):344. doi: 10.1186/s13063-017-2064-7. |